Metabolic syndrome associated with increased risk of endometrial cancer
the ONA take:
Past research has indicated that metabolic syndrome increased older women’s the risk of endometrial cancer, the most common cancer of the female reproductive organs. However, whether the association was due to obesity or metabolic syndrome was unclear.
A new study from the National Institutes of Health demonstrated that metabolic syndrome is associated with increased risk of endometrial cancer. Metabolic syndrome is a cluster of factors that increase a person’s risk of cardiovascular disease, stroke, diabetes, and other metabolic-related diseases.
Using the SEER-Medicare Linked Database, the researchers reviewed information from 16,323 women ages 65 years and older with endometrial cancer diagnosed between 1993 and 2007, along with 100,751 women who did not have the disease.
A diagnosis of metabolic syndrome was determined using criteria set by either the US National Cholesterol Education Program Adult Treatment Panel III (ATP III) or the International Diabetes Foundation.
The researchers found women with metabolic syndrome as determined by the ATP III criteria were 39% more likely to develop endometrial cancer, and those with metabolic syndrome as determined by International Diabetes Foundation criteria were 109% more likely to develop endometrial cancer. After accounting for overweight or obesity among the women, the risk of developing endometrial cancer were 21% higher and 17% higher, respectively.
In addition, excessive weight, hypertension, high triglycerides, and impaired fasting glucose—all factors in metabolic syndrome—increased women’s risk of developing endometrial cancer individually.
Whether the association with endometrial cancer was due to obesity or metabolic syndrome was unclear.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Immunotherapy and the Future of Prostate Cancer Treatment
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Use of Checkpoint Inhibitors in Urothelial Carcinoma
- Chemo + Radiotherapy Efficacious in Muscle-invasive Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Colorectal Cancer Risk Higher With Poor Metabolic Health vs Increased Weight
- Best Approach to Infection and Tumor Treatment: Contain or Eliminate?
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|